Company profile

HOLOGIC

Medical Imaging & Radiology

Company profile

About HOLOGIC

Hologic is a global medical technology company dedicated to improving women's health outcomes through innovative diagnostic and imaging solutions. Founded in 1985 and headquartered in the United States, Hologic operates in 36 countries with approximately 7,000 employees and holds over 4,100 patents. The company's mission centers on helping women live healthier lives by developing technologies that effectively detect, diagnose, and treat health conditions while raising the standard of care globally. Hologic's product portfolio spans multiple domains of women's health including breast health (mammography and imaging), gynecological health (surgical and diagnostic solutions), sexual health, skeletal health (bone density assessment), and body composition analysis. The company also operates a robust lab technologies division offering molecular diagnostics, cytology, oncology testing, and collection devices. During the COVID-19 pandemic, Hologic played a significant role in diagnostic testing, leveraging its molecular diagnostics capabilities. The company is committed to advancing women's health globally through its Global Access Initiative, philanthropy programs, and Project Health Equity. Hologic also created the Women's Health Index, an unprecedented research initiative studying the health and well-being of 3.9 billion women worldwide. The company emphasizes sustainability, quality, and innovation while working to break down barriers that prevent women from receiving necessary care. Hologic serves health systems, laboratories, clinics, and healthcare providers worldwide with a focus on delivering exceptional clinical results and patient outcomes.

Company description HOLOGIC official website

Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceLinkedIn X
Work at HOLOGIC?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • bone health
  • breast cancer
  • cervical cancer
  • COVID-19
  • gynecological conditions
  • HIV
  • infectious diseases
  • osteoporosis

Who it serves

  • Clinics
  • Government Health Programs
  • Health Systems
  • Healthcare Providers
  • Hospitals
  • Laboratories

Deployment & integration

Embedded · On Premise · Other deployment with recorded integration context.

Geographic context

Markets36 countries total · Australia · Canada · China · Denmark · France · Germany · Italy · Japan · Netherlands · New Zealand · Portugal · Singapore · Spain · Sweden · UK · USA
Company sourceOfficial website

Company milestones

Platform expansion

April 2026: Blackstone and TPG completed acquisition of Hologic (go-private transaction). June 2026: Released 2025 Sustainability Report marking 40 years of impact. June 2026: Secured patent victory against Siemens Healthineers. May 2026: Presented new data at ASCO 2026 on Breast Cancer Index Test. April 2026: Published new evidence on AI-powered mammography technology.

Partnerships

Recorded partners

  • U.S. and European governments for HIV testing programs

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

AI-Powered Mammography Technology

Artificial intelligence for enhanced breast cancer detection

Software · EmbeddedCompany source

Breast Cancer Index Test

Personalized genomic test for breast cancer treatment decisions

Service · OtherCompany source

Direct Load Tube Collection Kit

Sample collection device for molecular diagnostics

Device · OtherCompany source

DXA (Dual-Energy X-ray Absorptiometry)

Bone density measurement technology for osteoporosis screening

Device · On PremiseCompany source

Panther Fusion System

Molecular diagnostics platform for infectious disease testing

Platform · On PremiseCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

Research

Publications & preprints

Clinical utility of nucleic acid amplification testing for detection of sexually transmitted infections in women with symptomatic bacterial vaginosis and vulvovaginal candidiasis identified by conventional versus molecular diagnoses.

Journal of clinical microbiology · Aug 21, 2026

Vaginitis and Sexually Transmitted Infections Coinfections.

O&G open · Aug 1, 2026

Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · Jun 1, 2026

Mycoplasma genitalium infection and adverse perinatal outcomes.

American journal of obstetrics and gynecology · May 5, 2026

Long-read sequencing identifies aberrant fragmentation patterns linked to elevated cell-free DNA levels in cancer.

Genome biology · Apr 10, 2026

Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Breast (Edinburgh, Scotland) · Apr 1, 2026

Clinical validation

Clinical-trial records

DXA Study of Precision and Reliability

NCT03621306 · Mentioned · RECRUITING

Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant Treatment

NCT05297773 · Mentioned · COMPLETED

Prospective Case Collection Study for New Mammography Technologies

NCT05199701 · Sponsor · ACTIVE NOT RECRUITING

Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device

NCT06636539 · Sponsor · ACTIVE NOT RECRUITING

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

NCT07654231 · Mentioned · NOT YET RECRUITING

Multicomponent Program on a Group of Nonagenarians

NCT03886558 · Mentioned · COMPLETED

Regulatory

Regulatory records

Genius AI Detection 2.0

K243341 · 510k · Jul 31, 2025

“Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm”

DEN210035 · De Novo · Jan 31, 2024

Genius AI Detection 2.0 with CC-MLO Correlation

K230096 · 510k · May 23, 2023

Genius AI Detection 2.0

K221449 · 510k · Oct 6, 2022

Genius AI Detection

K201019 · 510k · Nov 18, 2020

Quantra

K163623 · 510k · Oct 20, 2017

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

39% decline in new HIV infections since 2010

Global HIV testing and treatment programs

Patent victory over Siemens Healthineers

Breast cancer detection technology

Shingo Prize for world-class quality culture

Hologic Costa Rica operations

Duke Women's Cancer Center

Personalized breast cancer survivorship care using Breast Cancer Index Test

Enabled personalized treatment decisions for extended endocrine therapy beyond one-size-fits-all approach

Hologic Costa Rica

World-class quality culture and operational excellence

Earned prestigious Shingo Prize for culture of excellence and world-class results

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

Malik Khan

Malik Khan

Corporate Vice President of Quality

LinkedIn

Mireille Akilian

Vice President of R&D

LinkedIn

Tanja Brycker

Executive (Data, Technology and AI)

Sami Diab

Associate Medical Director

Erica Wheeler

Executive (Cervical Cancer Prevention)

06 · Company updates

Updates from HOLOGIC

Recent articles published on HOLOGIC's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Medical Imaging & Radiology

Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon